caa a22 4500 555159507 CHVBK 20200406035039.0 cr unu---uuuuu 190202e201902 xx s 000 0 eng 10.1007/s11914-019-00502-4 doi (SERVAL)BIB_6E92DA5E8472 30659428 pmid 000459470600002 isiid Stopping Denosumab [Elektronische Daten] [O. Lamy, D. Stoll, B. Aubry-Rozier, E.G. Rodriguez] Denosumab discontinuation is associated with a rebound effect manifesting by an increased risk of multiple spontaneous vertebral fractures. The purpose of this review is to (1) better characterize this risk and (2) find solutions to avoid it. In the absence of a potent bisphosphonate prescription at denosumab discontinuation, the frequency of multiple vertebral fractures is common or frequent (≥ 1/100 and &lt; 1/10). In five recent case series, the median number of vertebral fractures was 5 within 7 to 20 months (median 11) after the last denosumab injection. Prescribing bisphosphonate before starting denosumab and/or after stopping denosumab may reduce this risk. However, only small case series have evaluated these strategies. After the second denosumab dose, there is a rebound effect with an increased risk of multiple vertebral fractures. A potent bisphosphonate prescribed at denosumab discontinuation could reduce this risk. As denosumab discontinuation is characterized by many uncertainties, denosumab is a second-line treatment for osteoporosis. Studies are urgently needed to define the management of denosumab discontinuation. Lamy O. aut Stoll D. aut Aubry-Rozier B. aut Rodriguez E.G. aut Current osteoporosis reports 17/1(2019-02), 8-15 17:1<8-15 2019 17 1 article serval SERVAL 700 1- Lamy O. aut SERVAL 700 1- Stoll D. aut SERVAL 700 1- Aubry-Rozier B. aut SERVAL 700 1- Rodriguez E.G. aut SERVAL 773 0- Current osteoporosis reports 17/1(2019-02), 8-15 17:1<8-15 2019 17 BK010053 XK010053 XK010000 SERVAL SERVAL SERVAL article